Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
07:30am, Monday, 23'rd Mar 2026
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for gene
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 20'th Mar 2026
PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for gene
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO
04:30am, Monday, 16'th Mar 2026
Cinctive Capital Management LP trimmed its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 50.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securi
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress
07:47am, Thursday, 12'th Mar 2026
Limb-girdle muscular dystrophy type R9 (LGMDR9, formerly 2I) is a rare genetic disease caused by mutations in the FKRP gene.
BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
03:02pm, Wednesday, 11'th Mar 2026
BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
02:00pm, Wednesday, 11'th Mar 2026
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified
Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up
02:34pm, Tuesday, 10'th Mar 2026
BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO
04:23am, Tuesday, 10'th Mar 2026
Victory Capital Management Inc. grew its position in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 42.0% during the third quarter, according to its most recent filing with the SEC. The firm owned
BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms
03:52am, Friday, 06'th Mar 2026
BridgeBio Pharma (NASDAQ: BBIO) CEO Neil Kumar outlined the company's recent clinical progress, commercial momentum, and near-term regulatory plans during a fireside chat at TD Cowen's 46th Annual Hea
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
07:30am, Wednesday, 04'th Mar 2026
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for gene
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates
08:31pm, Tuesday, 24'th Feb 2026
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $1.31 per share a year ago.
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
07:27pm, Tuesday, 24'th Feb 2026
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
04:01pm, Tuesday, 24'th Feb 2026
PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused o
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 28,053 Shares
04:49am, Tuesday, 24'th Feb 2026
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CEO Neil Kumar sold 28,053 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an averag
BridgeBio to Participate in March Investor Conferences
07:30am, Monday, 23'rd Feb 2026
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genet
